The company reported a net loss of $137 million in 2021, according to its annual filing with the Securities and Exchange Commission, following a reported net loss of nearly $40 million the year prior.
“I think the most important thing in drug development is to look at the science and be driven by the data,” Hu said. “In the last year, what we’ve done is we looked at the data and we conducted an extension where we re-boosted our initial patients.”production of antibodies against multiple COVID variants
To make it to that phase in the U.S. a vaccine must survive a small Phase 1 trial of a few dozen volunteers to establish safety and a larger Phase 2 trial to establish the optimal dosing of the treatment. The FDA dictates the steps of the highly-regulated process.